APO Research
Talk to an analyst

APO RESEARCH · REPORT

Postmenopausal Vaginal Atrophy (PVA) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Outlook and Growth Opportunities 2026

20 December 2025193 pages

Choose your research edition.

Industry ResearchPostmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Postmenopausal Vaginal Atrophy (PVA) Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Postmenopausal Vaginal Atrophy (PVA) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Postmenopausal Vaginal Atrophy (PVA) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Postmenopausal Vaginal Atrophy (PVA) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Postmenopausal Vaginal Atrophy (PVA) Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Postmenopausal Vaginal Atrophy (PVA) Therapeutics market include Teva Pharmaceuticals, Pfizer, Shionogi & Co, Novo Nordisk, Endoceutics and Accord Healthcare, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Postmenopausal Vaginal Atrophy (PVA) Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Postmenopausal Vaginal Atrophy (PVA) Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Postmenopausal Vaginal Atrophy (PVA) Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Postmenopausal Vaginal Atrophy (PVA) Therapeutics market.

Postmenopausal Vaginal Atrophy (PVA) Therapeutics Segment by Company

Teva Pharmaceuticals

Pfizer

Shionogi & Co

Novo Nordisk

Endoceutics

Accord Healthcare

Postmenopausal Vaginal Atrophy (PVA) Therapeutics Segment by Type

Drugs Treatment

Other Treatments

Postmenopausal Vaginal Atrophy (PVA) Therapeutics Segment by Application

Hospital

Clinic

Others

Postmenopausal Vaginal Atrophy (PVA) Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Postmenopausal Vaginal Atrophy (PVA) Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Postmenopausal Vaginal Atrophy (PVA) Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Postmenopausal Vaginal Atrophy (PVA) Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Postmenopausal Vaginal Atrophy (PVA) Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Postmenopausal Vaginal Atrophy (PVA) Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Postmenopausal Vaginal Atrophy (PVA) Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Postmenopausal Vaginal Atrophy (PVA) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Postmenopausal Vaginal Atrophy (PVA) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Postmenopausal Vaginal Atrophy (PVA) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Postmenopausal Vaginal Atrophy (PVA) Therapeutics industry.

Chapter 3: Detailed analysis of Postmenopausal Vaginal Atrophy (PVA) Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Postmenopausal Vaginal Atrophy (PVA) Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Postmenopausal Vaginal Atrophy (PVA) Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Trends Table 2. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Drivers Table 3. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Opportunities and Challenges Table 4. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Restraints Table 5. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Company, Product Type & Application Table 10. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Drugs Treatment Table 15. Significant Companies of Other Treatments Table 16. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type (2021-2026) Table 20. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Clinic Table 23. Significant Companies of Others Table 24. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application (2021-2026) Table 28. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application (2027-2032) Table 29. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Region (2021-2026) Table 32. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Region (2027-2032) Table 34. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Market Share by Country (2021-2026) Table 37. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Market Share by Country (2027-2032) Table 39. Teva Pharmaceuticals Company Information Table 40. Teva Pharmaceuticals Business Overview Table 41. Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio Table 43. Teva Pharmaceuticals Recent Development Table 44. Pfizer Company Information Table 45. Pfizer Business Overview Table 46. Pfizer Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Pfizer Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio Table 48. Pfizer Recent Development Table 49. Shionogi & Co Company Information Table 50. Shionogi & Co Business Overview Table 51. Shionogi & Co Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Shionogi & Co Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio Table 53. Shionogi & Co Recent Development Table 54. Novo Nordisk Company Information Table 55. Novo Nordisk Business Overview Table 56. Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio Table 58. Novo Nordisk Recent Development Table 59. Endoceutics Company Information Table 60. Endoceutics Business Overview Table 61. Endoceutics Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Endoceutics Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio Table 63. Endoceutics Recent Development Table 64. Accord Healthcare Company Information Table 65. Accord Healthcare Business Overview Table 66. Accord Healthcare Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Accord Healthcare Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio Table 68. Accord Healthcare Recent Development Table 69. Research Programs/Design for This Report Table 70. Authors List of This Report Table 71. Secondary Sources Table 72. Primary Sources List of Figures Figure 1. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Image Figure 2. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Drugs Treatment Image Figure 8. Other Treatments Image Figure 9. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Others Image Figure 15. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application (2021-2032) Figure 18. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 21. North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 27. South America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Drugs Treatment
  • Other Treatments
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Teva Pharmaceuticals
  • Pfizer
  • Shionogi & Co
  • Novo Nordisk
  • Endoceutics
  • Accord Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Dynamics
  1. 2.1 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Trends
  2. 2.2 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Drivers
  3. 2.3 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Industry Restraints
3 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market by Company
  1. 3.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Company Product Type and Application
  6. 3.6 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market by Type
  1. 4.1 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Type Introduction
  2. 4.1.1 Drugs Treatment
  3. 4.1.2 Other Treatments
  4. 4.2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Type
  5. 4.2.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Type (2021-2032)
  7. 4.2.3 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type (2021-2032)
5 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Market by Application
  1. 5.1 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Application
  6. 5.2.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Application (2021-2032)
  8. 5.2.3 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application (2021-2032)
6 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Regional Value Analysis
  1. 6.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Postmenopausal Vaginal Atrophy (PVA) Therapeutics Country-level Value Analysis
  1. 7.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Postmenopausal Vaginal Atrophy (PVA) Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceuticals
  2. 8.1.1 Teva Pharmaceuticals Company Information
  3. 8.1.2 Teva Pharmaceuticals Business Overview
  4. 8.1.3 Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceuticals Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio
  6. 8.1.5 Teva Pharmaceuticals Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 Shionogi & Co
  14. 8.3.1 Shionogi & Co Company Information
  15. 8.3.2 Shionogi & Co Business Overview
  16. 8.3.3 Shionogi & Co Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shionogi & Co Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio
  18. 8.3.5 Shionogi & Co Recent Developments
  19. 8.4 Novo Nordisk
  20. 8.4.1 Novo Nordisk Company Information
  21. 8.4.2 Novo Nordisk Business Overview
  22. 8.4.3 Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novo Nordisk Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio
  24. 8.4.5 Novo Nordisk Recent Developments
  25. 8.5 Endoceutics
  26. 8.5.1 Endoceutics Company Information
  27. 8.5.2 Endoceutics Business Overview
  28. 8.5.3 Endoceutics Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Endoceutics Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio
  30. 8.5.5 Endoceutics Recent Developments
  31. 8.6 Accord Healthcare
  32. 8.6.1 Accord Healthcare Company Information
  33. 8.6.2 Accord Healthcare Business Overview
  34. 8.6.3 Accord Healthcare Postmenopausal Vaginal Atrophy (PVA) Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Accord Healthcare Postmenopausal Vaginal Atrophy (PVA) Therapeutics Product Portfolio
  36. 8.6.5 Accord Healthcare Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst